Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) was upgraded by Mackie to a “hold” rating in a research note issued on Tuesday. The firm presently has a $3.10 target price on the stock, up from their previous target price of $1.00. Mackie’s price target suggests a potential upside of 206.93% from the company’s current price.

Several other analysts also recently weighed in on the company. Maxim Group reissued a “buy” rating and issued a $6.00 target price on shares of Intellipharmaceutics International in a report on Friday, June 30th. ValuEngine downgraded Intellipharmaceutics International from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded Intellipharmaceutics International from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.52.

TRADEMARK VIOLATION NOTICE: “Intellipharmaceutics International Inc. (IPCI) Raised to “Hold” at Mackie” was published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/26/intellipharmaceutics-international-inc-ipci-raised-to-hold-at-mackie.html.

A hedge fund recently raised its stake in Intellipharmaceutics International stock. Advisor Group Inc. raised its stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 57.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the period. Advisor Group Inc. owned approximately 0.16% of Intellipharmaceutics International worth $100,000 as of its most recent SEC filing. 4.24% of the stock is owned by institutional investors and hedge funds.

About Intellipharmaceutics International

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.